Effectiveness of survivorship programmes to enhance health-related quality of life of colorectal cancer survivors: a systematic review and meta-analysis of randomised controlled trials Authors: Pham Nhat Vi Do, Thi Khanh Nguyen, Yishu Qi, Kai Chow Choi, Thi Xuan Huong Hoang, Ba Phuoc Le, Yuen Tung Lam, Mankei Tse, Cho Lee Wong Published: 2026 ABSTRACT PurposeThis study aimed to assess the effectiveness of the survivorship programmes by synthesising and analysing the available evidence to enhance health-related quality of life (HRQoL) amongst colorectal cancer (CRC) survivors.MethodsTen English-language databases were searched from inception to June 2025 in this systematic review and meta-analysis. All randomised controlled trials (RCTs) were included. Available data were pooled in a meta-analysis using RevMan (version 5.4.0). Two independent reviewers performed the database searches, extracted the data, assessed the methodological quality by using the Cochrane Risk-of-Bias tool (version 2) and evaluated the overall quality of findings by using Cochrane GRADE.ResultsA total of 22 RCTs involving 2949 CRC survivors were identified. The meta-analysis results (thirteen studies) indicated a significant improvement in the physical (standardised mean difference [SMD] = 0.52, 95% confidence interval [CI, 0.18, 0.86], P = 0.002, I2 = 88%) and mental domains of HRQoL (SMD = 0.4, 95% CI [0.06, 0.74], P = 0.02, I2 = 86%). Sensitivity analysis involved reducing the heterogeneity after removing one study. No publication bias was found. The overall quality of findings was from ‘low’ to ‘moderate’.ConclusionsThe detailed components of the survivorship programme can enhance HRQoL in physical and mental domains, indicating its potential as valuable evidence for health providers to support CRC survivors post-treatment. Future research should focus on expanding the delivery of such programme comprehensively by integrating mobile health into a nurse-led approach to optimise geographic diversity and improve social HRQoL.Supplementary informationThe online version contains supplementary material available at 10.1007/s00520-026-10779-8. Introduction Colorectal cancer (CRC) is the third leading cause of cancer-related deaths for both men and women [1]. By 2030, the global burden of CRC is expected to increase by 60%, leading to an additional 2.2 million new cases and 1.1 million deaths [2]. Despite these alarming statistics, advancements in CRC treatments, including laparoscopic surgery, radiation therapy and chemotherapy, have remarkably improved the long-term survival rates for CRC survivors, marking what is known as cancer survivorship [3]. The overall 5-year survival rate ranges from 40 to 70% in countries [4, 5]. Cancer survivorship has many definitions. Mullan introduced the first term, outlining three phases: the acute phase, the extended phase and permanent survival [6]. In 2006, the Institute of Medicine expanded this definition to encompass the entire journey from initial diagnosis to the end of life [7]. However, most studies define the survivorship phase as the time following the completion of primary treatment (surgery, chemotherapy and radiotherapy) [8–11]. This review adopts the widely accepted survivorship definition, focusing on survivors who have completed primary treatment. The post-primary treatment period can be particularly challenging for those with a CRC diagnosis, reducing their health-related quality of life (HRQoL) [12]. HRQoL encompasses an individual’s perception of their life across physical, mental and social dimensions, aligning with the criteria outlined in WHO’s definition of health [13–15]. Several factors contribute to this decrease, including unmet information needs, limited access to support from healthcare providers after treatment [16] and the experience of CRC survivors’ symptoms, such as depression, anxiety, distress, fatigue and bowel dysfunction [8, 17]. With the growing population of CRC survivors, providing effective programmes to address their needs is essential. The Institute of Medicine recommends the development of survivorship programmes specifically to meet the supportive care needs of this group [18]. Since then, various organisations, including the National Comprehensive Cancer Network and the American Society of Clinical Oncology, have released guidelines to address these critical topics. Building upon previous recommendations, the American Cancer Society (ACS) released its CRC Survivorship Care Guidelines, recognising the gaps in survivorship resources and clinical follow-up in post-treatment. This guideline provides comprehensive care recommendations to help CRC survivors achieve optimal health and HRQoL. The key dimensions focus on four main areas: (1) surveillance for CRC recurrence and screening for second cancers, (2) management of the long-term physical and psychological effects of CRC treatment, (3) promotion of healthy behaviours and (4) coordination of care between specialists and primary care clinicians [19]. After the ACS guidelines were instituted in 2015, the systematic reviews of survivorship programmes have focused on only a single aspect of it, such as managing late effects or promotion of health, rather than the four dimensions [20–22]. As a result, survivors’ supportive needs are often not comprehensively addressed, which can lead to inappropriate treatment decisions or reduced treatment effectiveness, ultimately affecting their adherence and HRQoL [23]. The umbrella term ‘colorectal cancer patients’ in current studies includes those who are undergoing treatment or adjuvant chemotherapy/radiotherapy and those who have completed treatment [24, 25]. However, the needs of the two groups are different. Whilst the former group requires a focus on targeted therapy and management of side effects during treatment, the latter group requires more as they return to a ‘new normal’ life [26, 27]. Therefore, focusing on each group individually is necessary to meet their unmet needs. Meanwhile, the implementation in research and practice following the ACS guidelines remains limited. To the authors’ knowledge, a prior literature review provides an overview of the survivorship programme for CRC survivors post-treatment on the basis of ACS’s CRC survivorship care guidelines, which synthesised data from five databases, including 30 studies (five reviews, 12 randomised controlled trials [RCTs] and 13 non-RCTs). The results, as for the long-term physical and psychosocial effects of CRC treatment, indicated that the programmes could address ostomy issues and improve the distress, depression and anxiety of survivors. For health promotion, exercise can effectively reduce fatigue and improve HRQoL in the short term of less than three months [28]. The CRC surveillance programmes needed to be explored, and the care coordination programme showed improvement through survivorship care plan. However, that review was constrained by heterogeneous study designs (systematic reviews, RCTs and non-RCTs) and a limited search strategy (five databases), giving uncertain conclusions. Crucially, neither the ACS guidelines nor the existing literature review provides detailed guidance on key intervention components such as dosage, format, facilitators or delivery mode. This lack of detail leaves healthcare providers and survivors with inadequate support, which ultimately affects long-term HRQoL. To address this gap, this systematic review aimed to synthesise the available evidence on the effects of survivorship programmes, compared with usual care, on health-related quality of life among colorectal cancer survivors. Methods This systematic review followed the guidelines for reporting parallel group randomised trials on the basis of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement [29]. A prospective protocol was registered with the International Prospective Register of Systematic Reviews (PROSPERO ID: CRD42024580272). Inclusion and exclusion criteria This review included RCTs that focused on survivorship programmes aimed at managing HRQoL amongst CRC survivors. The exclusion criteria included conference abstracts, protocols, surveys, review studies and studies that lacked pre- and post-intervention assessments or did not report HRQoL. The details of the inclusion and exclusion criteria are described in Supplementary File 1. Data sources A systematic search was performed across 10 databases (PubMed, Cochrane Library, Scopus, CINALH Ultimate, Embase, OVID EMCARE, OVID Nursing, OVID Medline, PsycINFO and Web of Science) by using specific search strategies from the databases’ inception to June 2025. The reference lists of identified articles were manually searched by citation of the included studies’ reference lists and conducted forward citations to find any additional relevant studies not retrieved by the electronic database searches. The search utilised titles, abstracts, keywords, MeSH terms and no-date restrictions. Search strategies The search keywords for the databases included the following: (‘Colorectal cancer survivor’ OR ‘cancer’ OR ‘neoplasm’ OR ‘colon’ OR ‘rectal’ OR ‘colorectal’ OR ‘Cancer Survivors[Mesh]’) AND (‘survivorship’ OR ‘post-treatment’ OR ‘follow-up’ OR ‘Survivorship[Mesh]’ OR ‘intervention’) AND (‘RCT’ OR ‘Randomized Controlled Trial’) AND (‘health-related quality of life’ OR ‘Quality of life’). Further details about the search strategy are presented in Supplementary File 2. Study selection The PRISMA guidelines for reporting parallel group randomised trials were followed. After the database searches were completed, duplicate studies were removed manually using EndNote 20 software. Two independent reviewers (D.P.N.V. and K.N.T.) screened the remaining articles on the basis of the title and abstract related to the inclusion criteria. The full texts of potentially eligible articles were then downloaded and assessed for inclusion. Whenever the two reviewers could not reach an agreement, a third reviewer (W.C.L.) was consulted to make a final decision by majority. Data extraction Data extraction and summarisation were carried out independently by the two reviewers (D.P.N.V. and K.N.T.). If a consensus could not be reached, the opinion of the third reviewer (W.C.L.) was obtained. The extracted data included participant demographics; disease status; and details of the intervention, including components, duration, providers, formats and outcome measures. Methodological quality The Risk-of-Bias (version 2.0) tool was used to assess the methodological quality, focusing on trial design, conduct and reporting. The questions within each domain gathered information relevant to the risk of bias. On the basis of the responses, the tool generated proposed judgments of ‘low risk’, ‘high risk’ or ‘some concerns’ for each domain. Disagreements between the two reviewers were resolved through discussions with the third reviewer. The Grading of Recommendation, Assessment, Development and Evaluation (GRADE) system was used to assess the quality of evidence, which was classified with four levels: high, moderate, low and very low. The following five factors subsequently downgraded the initially high-quality findings from RCTs: risk of bias, inconsistency, indirectness, imprecision and biased reporting [30]. Data analysis RevMan (version 5.4) was used to pool the quantitative results for statistical meta-analysis. Standardised mean differences (SMDs) and 95% confidence intervals (CIs) were calculated because the studies reported continuous data with non-identical outcome measures. For insufficient data for pooling meta-analysis, the original authors of the included studies were contacted. Clinical heterogeneity was assessed on the basis of similarities in participants, settings, interventions and outcomes. Statistical heterogeneity was assessed via I2, which revealed percentages of 25%, 50% and 75% as low, moderate and high levels of heterogeneity, respectively [31]. Given the variability of survivorship programmes across the studies, data were pooled using a random-effect model [32]. SMDs of values 0.2, 0.5 and 0.8 were considered small, medium and large effects, respectively [33]. Data were pooled from the subscales of HRQOL instrument and categorised into the physical, psychological/emotional and social domains in meta-analysis. Subgroup analyses were conducted for the components of programmes: duration (short term (≤ 3 months) versus long term (over 3 months) [34], and formats such as mobile health (telephone, text message, mobile application, email and WeChat) versus face to face versus blended and providers (‘clinicians versus non-clinicians’ refers to individuals engaged in clinical work versus those who are not involved in direct patient care). Publication bias was performed when at least 10 studies were pooled for the same outcome through funnel plots and Egger’s regression test to assess asymmetry [35, 36]. Sensitivity analysis Leave-one-out sensitivity analysis was conducted by excluding one trial at a time to evaluate the stability of the pooled results [37]. Results Search results The database search yielded 12,075 articles and four articles for manual searching by citation-related search. After duplicates were removed, 8334 articles remained. The screening of titles and abstracts led to the exclusion of 8100 articles that did not meet the inclusion criteria. The full texts of the remaining 234 articles were then reviewed, resulting in the further exclusion of 212 articles. Ultimately, a total of 22 studies were included in the systematic review. Of these, 13 studies provided data for meta-analysis while the remaining 9 studies were not pooled quantitatively due to insufficient data and were synthesised narratively. The study retrieval and selection processes are presented in Fig. 1.Fig. 1Study retrieval and selection flow chart (PRISMA). From: Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71. https://doi.org/10.1136/bmj.n71. For more information, visit: http://www.prisma-statement.org/ Study retrieval and selection flow chart (PRISMA). From: Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71. https://doi.org/10.1136/bmj.n71. For more information, visit: http://www.prisma-statement.org/ Study characteristics Table 1 shows the characteristics of 22 RCTs [38–59]. The studies were conducted in 12 developed countries/regions from 2003 to 2024: the USA (N = 5), Australia, Mainland China (N = 3 studies each), South Korea, Taiwan (N = 2 studies each), New Zealand, Denmark, Germany, the UK, Canada, Netherlands, Hong Kong SAR (N = 1 study each). Table 1The characteristic of the included studiesIDReference, countrySample sizeAge (mean)/cancer stageControl groupInterventionOutcome measures/scalesComponentMode/providerDose and durationFollow-up1 Sun et al., 2024USA9355.2Ostomy, 6–24 months after treatmentAttention controlPromoting healthy behavioursIndividual, telephoneHealth coaches27 min/session10 sessions17 weeks9 weeksBowel function (MSK-BFI)Health-related quality of life (CHQoL-CRC)2 Park and Lee, 2024South Korea5856.9N/AAttention controlManagement of long-term physical and psychological side effectsIndividual, text messagesPhysician20 min/sessionTwice weekly12 weeks3, 6, 12 monthsHealth-related quality of life (EORTC QLQ-C30)3 Wang et al., 2023Taiwan15662.3Stage 1–2Usual carePromoting healthy behavioursIndividual, face to faceTelephoneOncology nursesTwo 60-min session and 12 weekly follow-up call6 monthsAnxiety and depression symptom (HADS)Health-related quality of life (FACIT-F; FACT-C)4McCombie et at., 2023New Zealand6867.3Stage 1–4Active controlManagement of long-term physical and psychological side effectsGroup, face to faceMindfulness teacher and psychologist2 h/week4 weeks8 weeks, 6 months post-baselineAnxiety and depression symptom (HADS)Health-related quality of life (SF-12)5 Jefford et al., 2023Australia15163.0Stage 1–2Usual careCoordinating careIndividual, face to faceOncologist, physician12 months6 months, 12 monthsHealth-related quality of life (EORTC QLQ-C30)6 Hovdenak et al., 2023Denmark33665.2Stage 0–3Standard careSurveillance and screening for the second cancer programmeManagement of long-term physical and psychological side effectsFace to face, telephone, emailNursesStructured one-time patient-led programme36 monthsHealth-related quality of life (FACT-C)7 Wang et al., 2022China5667.5Stage 1–3Routine careManagement of long-term physical and psychological side effectsWeChat/telephoneDietitians6 months6 monthsHealth-related quality of life (EORTC QLQ-C30)8 Chan et al., 2022USA4254.4Stage 1–4Active controlPromoting healthy behavioursFitbit wear, text messageNA2–3 times/week150 min/session12 weeks12 weeksHealth-related quality of life (FACT-C) (SF-36)9 Zhou and Sun, 2021China21064.0Stage 1–3Attention careManagement of long-term physical and psychological side effectsGroup, face to faceNursesOne session every two weeks12 months36 monthsAnxiety and depression symptom (HADS)Health-related quality of life (EORTC QLQ-C30)10 Zhang et al., 2020China15960.8Stage 1–4Conventional careManagement of long-term physical and psychological side effectsFace to faceOncologist or PsychologistOn session every two week3 months3 months, 6 monthsHealth-related quality of life (EORTC QLQ-C30)Anxiety and depression symptom (HADS)Distress scale (CRD)11 Yang et al., 2020Taiwan6860.0Ostomy, Stage 1–4Attention careManagement of long-term physical and psychological side effectsFace to faceOccupational therapist15–30 min1 month1-month,3 monthsHealth-related quality of life (WHOOQOL-BREF)12 Ho et al., 2020Hong Kong22365.2Ostomy, Stage 1–4Usual carePromoting healthy behavioursFace to face, telephoneDietitians and physicians2 sessions, followed by phone call every 2 weeks6 week to 6 months12 monthsHealth-related quality of life (SF-12)Health-related quality of life (FACT-C)Anxiety and depression symptom (HADS)13 Kim et al., 2019Korea7156.2Stage 2–3Usual carePromoting healthy behavioursFace to face, telephoneExercise trainers18 h/week during the first 6 weeks, increased to 27 h/week after 6 weeks12 weeks12 weeksHealth-related quality of life (FACT-C)Fatigue (FACIT-F)14 Brown et al., 2018USA39N/AStage 1–3Usual carePromoting healthy behavioursIn‐person, telephone and emailPhysician150–300 min per week6 months6 monthsHealth-related quality of life (SF‐36)Health-related quality of life (FACT-C)Fatigue (FSI39)Bowel dysfunction (NCCTG)15 Jefford et al., 2016) Australia22162.1Stage 1–3Usual careCoordinating careFace to face, TelephoneNurses60 min8 weeks2 months, 6 monthsDistress scale (BSI-18)Health-related quality of life (EORTC QLQ-C30)16 Cramer et al., 2016Germany5468.3Non-metastatic Stage 1–3Usual carePromoting healthy behavioursFace to faceYoga instructor90 min/week10 weeks10 weeks, 22 weeksHealth-related quality of life (FACT-C)Fatigue (FACIT-F)Anxiety and depression symptom (HADS)17 Hawkes et al., 2014b ,Australia41064.9Non-metastatic stage 1–4Usual careManagement of long-term physical and psychological side effectsTelephoneHealth coaches11 sessions6 months6 months, 12 monthsHealth-related quality of life (FACT-C)Distress scale (BSI-18)18 Pinto et al., 2013USA4659.5Stages 1–3Usual carePromoting healthy behavioursTelephoneOncologist5 days/week30 min/session12 weeks3, 6 and 12 monthsFatigue (FACIT-F)Health-related quality of life (SF‐36)Health-related quality of life (FACT-C)19 Bourke et al., 2011UK1869Stage 1–3Standard carePromoting healthy behavioursFace to facePhysiologist2 sessions/week12 weeks12 weeksHealth-related quality of life (FACT-C)Fatigue (FACIT-F)20 Courneya et al., 2003Canada10260.0N/AUsual carePromoting healthy behavioursTelephoneFitness consultant3–5 times/weeks20–30 min/session16 weeks16 weeksHealth-related quality of life (FACT-C)Anxiety and depression (CESD)Fatigue (FACIT-F)21 Mayer et al., 2018USA28457.8Stage 1–3Attention careManagement of long-term physical and psychological side effectsPromoting healthy behavioursAppsCoach150 min/week3 months3,6, 9 monthsHealth-related quality of life (FACT-C)Distress (NCCN)22 Custers et al., 2024Netherlands8463.7Stage 1–3Usual careManagement of long-term physical and psychological side effectsWebsite, telephonePsychologists8 sessions15–60 min/session14 weeks7 monthsHealth-related quality of life (EORTC QLQ-C30)Anxiety and depression symptom (HADS)Fatigue (CIS)BSI-18 The Brief Symptom Inventory 18, CESD The Centre for Epidemiological Studies Depression scale, CHQoL-CRC The City of Hope Quality of Life-Colorectal Cancer questionnaire, CIS The 20-item Checklist Individual Strength, CRD Cancer-related distress, EORTC QLQ-C30 The European Organization for Research and Treatment of Cancer Quality of Life Scale, FACIT-F Functional Assessment of Chronic Illness Therapy—Fatigue, FSI39 The Fatigue Symptom Inventory, HADS The Hospital Anxiety and Depression Scale, MSK-BFI The bowel function scale score, NCCN The National Comprehensive Cancer Network distress tool, NCCTG The North Central Cancer Treatment Group questionnaire, SF-12 The Short Form-12, SF-36 The Medical Outcomes Survey Short Form, WHOOQOL-BREF The World Health Organization Quality of Life Table 1The characteristic of the included studiesIDReference, countrySample sizeAge (mean)/cancer stageControl groupInterventionOutcome measures/scalesComponentMode/providerDose and durationFollow-up1 Sun et al., 2024USA9355.2Ostomy, 6–24 months after treatmentAttention controlPromoting healthy behavioursIndividual, telephoneHealth coaches27 min/session10 sessions17 weeks9 weeksBowel function (MSK-BFI)Health-related quality of life (CHQoL-CRC)2 Park and Lee, 2024South Korea5856.9N/AAttention controlManagement of long-term physical and psychological side effectsIndividual, text messagesPhysician20 min/sessionTwice weekly12 weeks3, 6, 12 monthsHealth-related quality of life (EORTC QLQ-C30)3 Wang et al., 2023Taiwan15662.3Stage 1–2Usual carePromoting healthy behavioursIndividual, face to faceTelephoneOncology nursesTwo 60-min session and 12 weekly follow-up call6 monthsAnxiety and depression symptom (HADS)Health-related quality of life (FACIT-F; FACT-C)4McCombie et at., 2023New Zealand6867.3Stage 1–4Active controlManagement of long-term physical and psychological side effectsGroup, face to faceMindfulness teacher and psychologist2 h/week4 weeks8 weeks, 6 months post-baselineAnxiety and depression symptom (HADS)Health-related quality of life (SF-12)5 Jefford et al., 2023Australia15163.0Stage 1–2Usual careCoordinating careIndividual, face to faceOncologist, physician12 months6 months, 12 monthsHealth-related quality of life (EORTC QLQ-C30)6 Hovdenak et al., 2023Denmark33665.2Stage 0–3Standard careSurveillance and screening for the second cancer programmeManagement of long-term physical and psychological side effectsFace to face, telephone, emailNursesStructured one-time patient-led programme36 monthsHealth-related quality of life (FACT-C)7 Wang et al., 2022China5667.5Stage 1–3Routine careManagement of long-term physical and psychological side effectsWeChat/telephoneDietitians6 months6 monthsHealth-related quality of life (EORTC QLQ-C30)8 Chan et al., 2022USA4254.4Stage 1–4Active controlPromoting healthy behavioursFitbit wear, text messageNA2–3 times/week150 min/session12 weeks12 weeksHealth-related quality of life (FACT-C) (SF-36)9 Zhou and Sun, 2021China21064.0Stage 1–3Attention careManagement of long-term physical and psychological side effectsGroup, face to faceNursesOne session every two weeks12 months36 monthsAnxiety and depression symptom (HADS)Health-related quality of life (EORTC QLQ-C30)10 Zhang et al., 2020China15960.8Stage 1–4Conventional careManagement of long-term physical and psychological side effectsFace to faceOncologist or PsychologistOn session every two week3 months3 months, 6 monthsHealth-related quality of life (EORTC QLQ-C30)Anxiety and depression symptom (HADS)Distress scale (CRD)11 Yang et al., 2020Taiwan6860.0Ostomy, Stage 1–4Attention careManagement of long-term physical and psychological side effectsFace to faceOccupational therapist15–30 min1 month1-month,3 monthsHealth-related quality of life (WHOOQOL-BREF)12 Ho et al., 2020Hong Kong22365.2Ostomy, Stage 1–4Usual carePromoting healthy behavioursFace to face, telephoneDietitians and physicians2 sessions, followed by phone call every 2 weeks6 week to 6 months12 monthsHealth-related quality of life (SF-12)Health-related quality of life (FACT-C)Anxiety and depression symptom (HADS)13 Kim et al., 2019Korea7156.2Stage 2–3Usual carePromoting healthy behavioursFace to face, telephoneExercise trainers18 h/week during the first 6 weeks, increased to 27 h/week after 6 weeks12 weeks12 weeksHealth-related quality of life (FACT-C)Fatigue (FACIT-F)14 Brown et al., 2018USA39N/AStage 1–3Usual carePromoting healthy behavioursIn‐person, telephone and emailPhysician150–300 min per week6 months6 monthsHealth-related quality of life (SF‐36)Health-related quality of life (FACT-C)Fatigue (FSI39)Bowel dysfunction (NCCTG)15 Jefford et al., 2016) Australia22162.1Stage 1–3Usual careCoordinating careFace to face, TelephoneNurses60 min8 weeks2 months, 6 monthsDistress scale (BSI-18)Health-related quality of life (EORTC QLQ-C30)16 Cramer et al., 2016Germany5468.3Non-metastatic Stage 1–3Usual carePromoting healthy behavioursFace to faceYoga instructor90 min/week10 weeks10 weeks, 22 weeksHealth-related quality of life (FACT-C)Fatigue (FACIT-F)Anxiety and depression symptom (HADS)17 Hawkes et al., 2014b ,Australia41064.9Non-metastatic stage 1–4Usual careManagement of long-term physical and psychological side effectsTelephoneHealth coaches11 sessions6 months6 months, 12 monthsHealth-related quality of life (FACT-C)Distress scale (BSI-18)18 Pinto et al., 2013USA4659.5Stages 1–3Usual carePromoting healthy behavioursTelephoneOncologist5 days/week30 min/session12 weeks3, 6 and 12 monthsFatigue (FACIT-F)Health-related quality of life (SF‐36)Health-related quality of life (FACT-C)19 Bourke et al., 2011UK1869Stage 1–3Standard carePromoting healthy behavioursFace to facePhysiologist2 sessions/week12 weeks12 weeksHealth-related quality of life (FACT-C)Fatigue (FACIT-F)20 Courneya et al., 2003Canada10260.0N/AUsual carePromoting healthy behavioursTelephoneFitness consultant3–5 times/weeks20–30 min/session16 weeks16 weeksHealth-related quality of life (FACT-C)Anxiety and depression (CESD)Fatigue (FACIT-F)21 Mayer et al., 2018USA28457.8Stage 1–3Attention careManagement of long-term physical and psychological side effectsPromoting healthy behavioursAppsCoach150 min/week3 months3,6, 9 monthsHealth-related quality of life (FACT-C)Distress (NCCN)22 Custers et al., 2024Netherlands8463.7Stage 1–3Usual careManagement of long-term physical and psychological side effectsWebsite, telephonePsychologists8 sessions15–60 min/session14 weeks7 monthsHealth-related quality of life (EORTC QLQ-C30)Anxiety and depression symptom (HADS)Fatigue (CIS)BSI-18 The Brief Symptom Inventory 18, CESD The Centre for Epidemiological Studies Depression scale, CHQoL-CRC The City of Hope Quality of Life-Colorectal Cancer questionnaire, CIS The 20-item Checklist Individual Strength, CRD Cancer-related distress, EORTC QLQ-C30 The European Organization for Research and Treatment of Cancer Quality of Life Scale, FACIT-F Functional Assessment of Chronic Illness Therapy—Fatigue, FSI39 The Fatigue Symptom Inventory, HADS The Hospital Anxiety and Depression Scale, MSK-BFI The bowel function scale score, NCCN The National Comprehensive Cancer Network distress tool, NCCTG The North Central Cancer Treatment Group questionnaire, SF-12 The Short Form-12, SF-36 The Medical Outcomes Survey Short Form, WHOOQOL-BREF The World Health Organization Quality of Life The characteristic of the included studies Sun et al., 2024 USA 55.2 Ostomy, 6–24 months after treatment Individual, telephone Health coaches 27 min/session 10 sessions 17 weeks Bowel function (MSK-BFI) Health-related quality of life (CHQoL-CRC) Park and Lee, 2024 South Korea 56.9 N/A Individual, text messages Physician 20 min/session Twice weekly 12 weeks Wang et al., 2023 Taiwan 62.3 Stage 1–2 Individual, face to face Telephone Oncology nurses Anxiety and depression symptom (HADS) Health-related quality of life (FACIT-F; FACT-C) McCombie et at., 2023 New Zealand 67.3 Stage 1–4 Group, face to face Mindfulness teacher and psychologist 2 h/week 4 weeks Anxiety and depression symptom (HADS) Health-related quality of life (SF-12) Jefford et al., 2023 Australia 63.0 Stage 1–2 Individual, face to face Oncologist, physician Hovdenak et al., 2023 Denmark 65.2 Stage 0–3 Surveillance and screening for the second cancer programme Management of long-term physical and psychological side effects Face to face, telephone, email Nurses Wang et al., 2022 China 67.5 Stage 1–3 WeChat/telephone Dietitians Chan et al., 2022 USA 54.4 Stage 1–4 Fitbit wear, text message NA 2–3 times/week 150 min/session 12 weeks Zhou and Sun, 2021 China 64.0 Stage 1–3 Group, face to face Nurses One session every two weeks 12 months Anxiety and depression symptom (HADS) Health-related quality of life (EORTC QLQ-C30) Zhang et al., 2020 China 60.8 Stage 1–4 Face to face Oncologist or Psychologist On session every two week 3 months Health-related quality of life (EORTC QLQ-C30) Anxiety and depression symptom (HADS) Distress scale (CRD) Yang et al., 2020 Taiwan 60.0 Ostomy, Stage 1–4 Face to face Occupational therapist 15–30 min 1 month 1-month, 3 months Ho et al., 2020 Hong Kong 65.2 Ostomy, Stage 1–4 Face to face, telephone Dietitians and physicians 2 sessions, followed by phone call every 2 weeks 6 week to 6 months Health-related quality of life (SF-12) Health-related quality of life (FACT-C) Anxiety and depression symptom (HADS) Kim et al., 2019 Korea 56.2 Stage 2–3 Face to face, telephone Exercise trainers 18 h/week during the first 6 weeks, increased to 27 h/week after 6 weeks 12 weeks Health-related quality of life (FACT-C) Fatigue (FACIT-F) Brown et al., 2018 USA N/A Stage 1–3 In‐person, telephone and email Physician 150–300 min per week 6 months Health-related quality of life (SF‐36) Health-related quality of life (FACT-C) Fatigue (FSI39) Bowel dysfunction (NCCTG) Jefford et al., 2016) Australia 62.1 Stage 1–3 Face to face, Telephone Nurses 60 min 8 weeks Distress scale (BSI-18) Health-related quality of life (EORTC QLQ-C30) Cramer et al., 2016 Germany 68.3 Non-metastatic Stage 1–3 Face to face Yoga instructor 90 min/week 10 weeks Health-related quality of life (FACT-C) Fatigue (FACIT-F) Anxiety and depression symptom (HADS) Hawkes et al., 2014b , Australia 64.9 Non-metastatic stage 1–4 Telephone Health coaches 11 sessions 6 months Health-related quality of life (FACT-C) Distress scale (BSI-18) Pinto et al., 2013 USA 59.5 Stages 1–3 Telephone Oncologist 5 days/week 30 min/session 12 weeks Fatigue (FACIT-F) Health-related quality of life (SF‐36) Health-related quality of life (FACT-C) Bourke et al., 2011 UK 69 Stage 1–3 Face to face Physiologist 2 sessions/week 12 weeks Health-related quality of life (FACT-C) Fatigue (FACIT-F) Courneya et al., 2003 Canada 60.0 N/A Telephone Fitness consultant 3–5 times/weeks 20–30 min/session 16 weeks Health-related quality of life (FACT-C) Anxiety and depression (CESD) Fatigue (FACIT-F) Mayer et al., 2018 USA 57.8 Stage 1–3 Management of long-term physical and psychological side effects Promoting healthy behaviours Apps Coach 150 min/week 3 months Health-related quality of life (FACT-C) Distress (NCCN) Custers et al., 2024 Netherlands 63.7 Stage 1–3 Website, telephone Psychologists 8 sessions 15–60 min/session 14 weeks Health-related quality of life (EORTC QLQ-C30) Anxiety and depression symptom (HADS) Fatigue (CIS) BSI-18 The Brief Symptom Inventory 18, CESD The Centre for Epidemiological Studies Depression scale, CHQoL-CRC The City of Hope Quality of Life-Colorectal Cancer questionnaire, CIS The 20-item Checklist Individual Strength, CRD Cancer-related distress, EORTC QLQ-C30 The European Organization for Research and Treatment of Cancer Quality of Life Scale, FACIT-F Functional Assessment of Chronic Illness Therapy—Fatigue, FSI39 The Fatigue Symptom Inventory, HADS The Hospital Anxiety and Depression Scale, MSK-BFI The bowel function scale score, NCCN The National Comprehensive Cancer Network distress tool, NCCTG The North Central Cancer Treatment Group questionnaire, SF-12 The Short Form-12, SF-36 The Medical Outcomes Survey Short Form, WHOOQOL-BREF The World Health Organization Quality of Life All studies included a total of 2949 CRC survivors with sample sizes ranging from 18 to 410 participants. The average age of the survivors varied from 54.4 to 68.26 years. Three studies reported that the survivors had an ostomy following treatment. Two studies reported that participants were in the early stages 1–2 of the disease, eleven in stage 3 and five in stage 4 (late-stage with metastasis). Interventions Based on the guidelines suggested by the ACS, four main components of the survivorship programmes were identified (Table S1). Most of the survivorship programmes (N = 11) in the included studies focus on promoting health behaviours, such as exercises and a healthy diet. Eight studies explored various forms of aerobic exercise, resistance training, walking, cycling, yoga and core stabilisation exercises, which were conducted under supervision or in a home-based setting [46, 51–53, 55, 57–59]. Additionally, two studies provided dietary interventions that included structured diet regimens, such as reductions in red and processed meat intake and low-fat diets, along with dietary counselling [38, 45]. One study combined exercise and nutritional interventions [50]. Furthermore, many programmes (N = 9) emphasised managing long-term physical and psychological side effects by educational and psychological interventions. For education, two studies offered colostomy education with self-management techniques, potential late effects and alarm symptoms [41, 44] while three studies provided healthy lifestyle education related to work and wellness [39, 49, 52]. For psychological intervention, one study utilised acceptance and commitment techniques for psychoeducation [56], and three studies implemented psychological interventions that incorporated music, guided imagery and cognitive restructuring to reduce stress and control emotion [48]; mindfulness [42]; and psychoeducation, cognitive restructuring, behaviour modification and relaxation [40]. Additionally, one study used reminiscence therapy to help individuals express their thoughts and feelings about cancer [47]. Two of the programmes promoted care coordination. One study involved follow-up care shared between hospital-based oncologists and survivors’ general physicians to monitor CRC recurrence after discharge, instead of traditional hospital-based follow-up care [43]. Another study provided a survivorship care plan that included tailored information on treatment and follow-up recommendations from health providers [54]. However, only one study focused on CRC surveillance and screening for second cancer, such as educating survivors about the signs of new cancers [44]. Delivery mode Seven programmes were conducted face to face. Six studies utilised social media platforms for support, including WeChat, application, email and text messages. Six studies employed a combination of face to face and telephone, and three studies were delivered solely through telephone. Duration In terms of programme duration, six studies lasted from 6 months to 3 years, three studies lasted for 16 weeks, seven studies were conducted for 12 weeks, five were conducted from 4 to 10 weeks and 15 studies conducted the follow-up after post-treatment. Each programme ranged from 4 to 24 sessions, and the frequency between sessions averaged weekly to monthly. Deliverer Four studies were delivered by nurses; five by oncologists/physicians; eleven by health-related professionals, such as occupational therapists, psychologists, dietitians, fitness trainers and yoga instructors; and one study combined physicians and dietitians. Measurements This review included six different scales to assess various types of HRQoL: the City of Hope Quality of Life-Colorectal Cancer questionnaire (N = 1), the Functional Assessment of Cancer Therapy-Colorectal (FACT-C, N = 12), the European Organization for Research and Treatment of Cancer Quality of Life Scale (EORTC QLQ-C30, N = 7), the Short Form-12 (SF-12, N = 2), the World Health Organization Quality of Life (WHOOQOL-BREF, N = 1) and the Medical Outcomes Survey Short Form (SF‐36, N = 3). It also included other scales, including distress (N = 3), depression (N = 2), anxiety (N = 1), bowel dysfunction (N = 2) and fatigue (N = 2). Methodological quality All studies consistently measured outcomes for the experimental groups and adhered to the correct statistical analyses and trial designs. Two studies were assessed as ‘high risk’ due to deviations from missing outcome data [42] and measurement of the outcome [49]. Other studies raised ‘some concerns’ regarding insufficient information on allocation concealment, non-blindness of intervention providers and outcome assessors. All studies reported sufficient information on predetermined data analysis plans or protocols. Overall, the studies ranged from having some concerns to a high risk of bias in methodological quality (Fig. 2).Fig. 2Risk-of-Bias 2.0 (RoBs) Risk-of-Bias 2.0 (RoBs) The quality of the studies included in this review was evaluated using the GRADE system. The quality of evidence for the HRQoL outcome was downgraded to the range of ‘very low’ and ‘low’ because of the risk of bias, high heterogeneity and imprecision, whereas that of other outcomes was from ‘low’ to ‘moderate’ (Supplementary File 3). Publication bias No publication bias was found for the included studies with physical and mental HRQoL outcomes, with Egger’s test results of t = 0.789, df = 11 and P = 0.446 and t = 1.379, df = 10 and P = 0.197, respectively (Fig. 3).Fig. 3Publication bias; A HRQoL_(Physical). B HRQoL_(Mental) Publication bias; A HRQoL_(Physical). B HRQoL_(Mental) Effects of survivorship programmes on health-related QoL HRQoL The meta-analysis results indicated a significant improvement in HRQoL related to physical (13 studies with 1469 CRC survivors) [39, 42, 45–49, 51, 53–56, 59] and mental (11 studies with 1239 CRC survivors) [39, 42, 45, 46, 48, 49, 51, 54–56, 59] domains following the survivorship programmes: (SMD = 0.52, 95% CI [0.18, 0.86], P = 0.002, I2 = 88%) and (SMD = 0.4, 95% CI [0.06, 0.74], P = 0.02, I2 = 86%), respectively (Fig. 4A and B). However, a non-significant improvement was observed in HRQoL related to social domain (08 studies with 647 CRC survivors) [39, 45, 46, 49, 51, 54, 55, 59] (SMD = 0.51, 95% CI [−0.13, 1.15], P = 0.12, I2 = 93%), as shown in Fig. 4C. Amongst the 22 studies, nine reported insufficient data for meta-analysis due to omitting the standard deviation or reporting selective statistics only, such as adjusted mean differences, slope coefficients and P-values. Narrative synthesis was conducted to assess the effectiveness of this outcome. Seven studies showed no significant differences in HRQoL indicators, suggesting that the control group had similar features to the intervention to promote exercise, diet and psychological well-being, leading to no significant difference [38, 43, 44, 50, 52, 57, 58]. Meanwhile, one study demonstrated that the intervention group achieved significantly higher HRQoL scores compared to the control group immediately post-intervention (P = 0.012) [41], while another noted improvement in the intervention group after 7 months [40].Fig. 4Forest plot of the survivorship programme comparing the survivorship programme (experimental) with the usual care (control) in health-related quality of life outcome. Legend: Forest plot of the survivorship programme. Squares represent the effect sizes of individual studies, while diamonds indicate the summarised effect sizes. The horizontal lines denote the upper and lower bounds of the 95% confidence intervals. P-values greater than 0.05 are considered to indicate statistical non-significance Forest plot of the survivorship programme comparing the survivorship programme (experimental) with the usual care (control) in health-related quality of life outcome. Legend: Forest plot of the survivorship programme. Squares represent the effect sizes of individual studies, while diamonds indicate the summarised effect sizes. The horizontal lines denote the upper and lower bounds of the 95% confidence intervals. P-values greater than 0.05 are considered to indicate statistical non-significance Sensitivity analysis, which involved the removal of the heterogeneous study [45], had distinct effects. For the HRQoL in mental domain, heterogeneity was eliminated (P = 0.04, I2 = 0%). For the HRQoL in physical domain, its removal reduced the heterogeneity from high to moderate (P = 0.01, I2 = 65%), as shown in Supplementary File 4. Sensitivity analysis was also performed by removing two studies with a high risk of bias, and this made no significant difference to the overall results. Subgroup analyses were conducted to examine the duration, formats and providers of the programme with HRQoL in physical and mental domains. Notably, the subgroup identified significant difference for duration, with long-term programmes (over 3 months) showing a greater effect on physical HRQoL than short-term programmes (≤ 3 months, P = 0.02). For providers, clinician-led programmes demonstrated a significantly greater effect on physical HRQoL than non-clinician-led programmes (P = 0.01). By contrast, whilst the subgroup differences were non-significant across the formats (P = 0.66 for physical and P = 0.29 for mental), the mHealth format was associated with the largest effect size compared with the face to face and blended formats. Distress, anxiety and depression Three studies tested distress in 287 CRC survivors [40, 42, 48], eight studies measured anxiety in 880 CRC survivors [40–42, 47, 48, 50, 55, 59] and nine studies measured depression in 960 CRC survivors [40–42, 47, 48, 50, 51, 55, 59]. These studies were pooled and included in the meta-analysis. Significant effects were found for symptoms of distress (SMD = −0.55, 95% CI [−0.78, −0.31], P < 0.0001, I2 = 0%), anxiety (SMD = −0.35, 95% CI [−0.53, −0.17], P = 0.0001, I2 = 41%) and depression (SMD = −0.23, 95% CI [−0.36, −0.1], P = 0.0004, I2 = 0%), as shown in Supplementary Files 5A–C). Fatigue Eight studies that measured fatigue in 755 CRC survivors were pooled and included in the meta-analysis [40, 41, 44, 51, 55, 57–59]. No significant effects were found for fatigue (SMD = 0.007, 95% CI [−0.07, 0.22], P = 0.31, I2 = 0%; Supplementary File 5D). Bowel function Two studies that measured bowel function in 338 CRC survivors were pooled and included in the meta-analysis [38, 44]. No significant effects were found for bowel function (SMD = −0.01, 95% CI [−0.35, 0.32], P = 0.93, I2 = 51%; Supplementary File 5E). Discussion This systematic review and meta-analysis was conducted to assess the effectiveness of survivorship programmes for improving post-treatment HRQoL in CRC survivors. A total of 22 RCTs involving 2949 CRC survivors were included. The meta-analysis results (13 studies) indicated that the programmes had a significant positive effect on the physical and mental domains of HRQoL and on anxiety, depression and distress. However, no significant effects were found for the social domain of HRQoL, fatigue and bowel function. This meta-analysis found that these programmes did not have significant effects on the social domain of HRQoL, which may be associated with finances, relationships, social activities or work performance post-treatment, because such factors are often perceived differently by each individual [60, 61]. The mean age of CRC survivors in the present study ranged from 54.4 to 68.26 years, highlighting a distinct difference between the two groups: the working group (60 years or younger) and the retired group (older 60 years). This division strengthened the varying social needs of each group. The former group often faced pressures related to work or finances, whereas the latter concentrated on family relationships and personal interests. Besides, the characteristic heterogeneity amongst CRC survivors in the present study, including ostomy status, stage and metastasis, is likely a confounding factor that influenced the reported HRQoL scores. In addition, the timing of HRQoL score assessment in the programmes varies, as well as the use of different scales. This difference contributes to the high heterogeneity observed in this review, underscoring the need for rigorous methodological research to evaluate the effectiveness of such programmes moving forward. This review identified key programme components for improving HRQoL in CRC survivors. This finding indicated a heterogeneous service delivery model for CRC survivors. The meta-analysis results for subgroups revealed that the survivorship programmes provided by clinicians had a greater effect on HRQoL than those led by non-clinicians. Besides, amongst clinician-led providers, studies have emphasised the vital role of nurses in supporting CRC survivors. One key finding is that patients expect nurses to provide information about the disease and treatment-related side effects, offer hope and advocate on their behalf [62]. Because nurses also serve as educators, coordinators, monitoring providers and palliative care providers [63]. Many reported enhanced satisfaction with their care and a sense of safety post-discharge due to continued contact with nurses who facilitated their transition [64]. Given these insights, future studies on survivorship programmes led by nurses are warranted to further explore and enhance the support provided to this vulnerable group. The subgroup meta-analysis indicated that the improvements in physical HRQoL are more pronounced in the long term (> 3 months) rather than the short term as prior reported [28]. Previous research demonstrated that HRQoL scores tend to improve after 4 months and continue thereafter [65, 66]. However, if an approach that includes monitoring survivors’ adherence is adopted for interventions, the scores may improve within the initial 3 months [67]. Furthermore, our analysis revealed that mHealth-based programmes yielded a more substantial effect on HRQoL than face to face or blended formats. This finding underscores the pivotal role of technology in enhancing the patient-provider relationship and aligns with previous meta-analyses reporting significant HRQoL improvements among breast cancer survivors utilising mobile health platforms [68]. The interventions in this review leveraged diverse platforms, including mobile applications, SMS, websites, WeChat and wearable devices like Fitbit, to facilitate education and treatment adherence. Such mHealth formats appear uniquely suited for cancer survivors post-discharge, providing flexible and accessible support during the transition to recovery [69]. However, despite these benefits, rapid disengagement and declining adherence remain critical barriers [70]. Future research should prioritise a co-design approach to develop mHealth solutions tailored to survivors’ specific preferences and real-world needs, thereby ensuring sustained engagement and long-term effectiveness. Notably, the demographic data in the present study were exclusively from CRC survivors in developed countries, highlighting a significant lack of geographic diversity, especially given the increasing prevalence of CRC in developing nations [71]. The implementation of mHealth in these regions should be approached with caution, as its effectiveness is closely tied to cultural factors. For example, many survivors may be more familiar with traditional healthcare services with face-to-face consultations than mHealth solutions. Hence, more research in developing countries is urgently needed to explore mHealth-based survivorship programmes to optimise individual survivorship and enhance HRQoL. Study strengths and limitations This systematic review and meta-analysis of RCTs contributes to the evidence on the details of components and the effectiveness of survivorship programmes in enhancing HRQoL in CRC survivors followed the ACS guidelines. However, this review has several limitations. Firstly, the inclusion of English-language publications only may have introduced a geographic bias, thus limiting the generalisability of the findings beyond predominantly English-speaking regions. Secondly, the exclusion of conference abstracts, dissertations and other grey literature may have resulted in selection bias. Thirdly, the overall methodological quality of the included studies was rated as having ‘some concerns’, which should be considered when interpreting the results. However, both the primary meta-analysis and sensitivity analysis, performed after excluding two studies at high risk of bias, indicate that the survivorship programmes were more effective than usual care. Therefore, the inclusion of studies at high risk of bias is unlikely to have influenced the overall findings. Finally, all included studies measured HRQoL, and this focus may have led to the underreporting of other relevant outcomes. However, this meta-analysis not only reported HRQoL outcomes but also substantially included psychological and physical symptoms that are known to influence HRQoL. Therefore, healthcare providers could consider this study as a viable option to improve comprehensive health outcomes for CRC survivors. Implications for practice This systematic review and meta-analysis provides important evidence for the design of survivorship programmes for CRC survivors. Future studies should control for potential confounders, including differences in demographics and culture, which may influence intervention effectiveness in diverse populations, especially in developing countries. Furthermore, the frequency and format of intervention (e.g. mHealth) should be carefully considered given their association with health behaviours and barriers to mHealth use. The optimal approach is through a co-design, where healthcare providers, developers and CRC survivors (end-users) may collaborate closely to develop mHealth-based programmes. This approach ensures that programmes are personalised to specific needs, considers sociodemographic factors and can be effectively integrated into local health systems. Conclusion This systematic review evaluated the survivorship programmes effectively improved HRQoL and reduced psychological. Components of such programmes include education, psychological intervention, exercise, diet programmes and survivorship care plan. Moreover, a nurse-led approach combined with the mHealth format post-treatment is expected to incorporate the four elements of ACS. Future studies that integrate these elements into mHealth initiatives to help CRC survivors remotely access timely medical care are warranted. Supplementary information Below is the link to the electronic supplementary material.ESM 1(DOCX 979 KB) (DOCX 979 KB)